# LifeStance Health Group, Inc.: overview

LFST · Nasdaq · CIK 1845257 · [Healthcare](/sectors/healthcare.md) · fiscal year ends Dec 31

Pages: [Overview](/companies/lfst.md) · [Financials](/companies/lfst/financials.md) · [Filings](/companies/lfst/filings.md) · [Insiders](/companies/lfst/insiders.md)

Latest reported revenue: [$435.4m](/filings/0001193125-26-338107.md) for Q2 FY2026, three months to 2026-06-30, from the 10-Q filed Aug 6, 2026 (XBRL us-gaap:Revenues, accession 0001193125-26-338107).

## Last eight quarters

| Line item | Unit | Q3 FY2024 (2024-09-30) | Q4 FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q4 FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Revenue | $m | [313](/filings/0001193125-25-269712.md) | [325 d](/filings/0001193125-26-071462.md) | [333](/filings/0001193125-26-211814.md) | [345](/filings/0001193125-26-338107.md) | [364](/filings/0001193125-25-269712.md) | [382 d](/filings/0001193125-26-071462.md) | [403](/filings/0001193125-26-211814.md) | [435](/filings/0001193125-26-338107.md) |
| Gross margin | % | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported |
| Operating margin | % | [0.0%](/filings/0001193125-25-269712.md) | [0.3% d](/filings/0001193125-26-071462.md) | [0.5%](/filings/0001193125-26-211814.md) | [(0.9%)](/filings/0001193125-26-338107.md) | [2.0%](/filings/0001193125-25-269712.md) | [4.7% d](/filings/0001193125-26-071462.md) | [5.5%](/filings/0001193125-26-211814.md) | [7.0%](/filings/0001193125-26-338107.md) |
| Net margin | % | [0.2%](/filings/0001193125-26-211814.md) | [(2.2%) d](/filings/0001193125-26-071462.md) | [0.2%](/filings/0001193125-26-211814.md) | [(1.1%)](/filings/0001193125-26-338107.md) | [0.3%](/filings/0001193125-25-269712.md) | [3.1% d](/filings/0001193125-26-071462.md) | [3.5%](/filings/0001193125-26-211814.md) | [5.4%](/filings/0001193125-26-338107.md) |
| Diluted EPS | $ per share | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported |
| Free cash flow | $m | [17.7 d](/filings/0001193125-25-269712.md) | [56.0 d](/filings/0001193125-26-071462.md) | [(10.3)](/filings/0001193125-26-211814.md) | [56.6 d](/filings/0001193125-26-338107.md) | [17.0 d](/filings/0001193125-25-269712.md) | [46.6 d](/filings/0001193125-26-071462.md) | [22.3](/filings/0001193125-26-211814.md) | [87.9 d](/filings/0001193125-26-338107.md) |

- Revenue. XBRL Revenue: us-gaap:Revenues. Derived values: 12-month figure less the 9-month figure.
- Gross margin (gross profit / revenue). XBRL Revenue: us-gaap:Revenues. Derived values: 12-month figure less the 9-month figure.
- Operating margin (operating income / revenue). XBRL Operating income: us-gaap:OperatingIncomeLoss; Revenue: us-gaap:Revenues. Derived values: 12-month figure less the 9-month figure.
- Net margin (net income / revenue). XBRL Net income: us-gaap:NetIncomeLoss; Revenue: us-gaap:Revenues. Derived values: 12-month figure less the 9-month figure.
- Diluted EPS. XBRL not reported.
- Free cash flow (operating cash flow − capital expenditure). XBRL Operating cash flow: us-gaap:NetCashProvidedByUsedInOperatingActivities; Capital expenditure: us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. Derived values: 9-month figure less the 6-month figure; 12-month figure less the 9-month figure; 6-month figure less the 3-month figure.

## Last five fiscal years

| Line item | Unit | FY2021 (2021-12-31) | FY2022 (2022-12-31) | FY2023 (2023-12-31) | FY2024 (2024-12-31) | FY2025 (2025-12-31) |
| --- | --- | ---: | ---: | ---: | ---: | ---: |
| Revenue | $m | [1.4](/filings/0000950170-22-004096.md) | [860](/filings/0000950170-25-029100.md) | [1,056](/filings/0001193125-26-071462.md) | [1,251](/filings/0001193125-26-071462.md) | [1,424](/filings/0001193125-26-071462.md) |
| Gross margin | % | not reported | not reported | not reported | not reported | not reported |
| Operating margin | % | [(19816.8%)](/filings/0000950170-24-022131.md) | [(24.5%)](/filings/0000950170-25-029100.md) | [(17.9%)](/filings/0001193125-26-071462.md) | [(2.5%)](/filings/0001193125-26-071462.md) | [1.7%](/filings/0001193125-26-071462.md) |
| Net margin | % | [(21259.3%)](/filings/0000950170-24-022131.md) | [(25.1%)](/filings/0000950170-25-029100.md) | [(17.6%)](/filings/0001193125-26-071462.md) | [(4.6%)](/filings/0001193125-26-071462.md) | [0.7%](/filings/0001193125-26-071462.md) |
| Diluted EPS | $ per share | not reported | not reported | not reported | not reported | not reported |
| Free cash flow | $m | [(85.1)](/filings/0000950170-24-022131.md) | [(26.5)](/filings/0000950170-25-029100.md) | [(57.4)](/filings/0001193125-26-071462.md) | [85.7](/filings/0001193125-26-071462.md) | [110](/filings/0001193125-26-071462.md) |

- Revenue. XBRL Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax; Revenue: us-gaap:Revenues.
- Gross margin (gross profit / revenue). XBRL Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax; Revenue: us-gaap:Revenues.
- Operating margin (operating income / revenue). XBRL Operating income: us-gaap:OperatingIncomeLoss; Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax; Revenue: us-gaap:Revenues.
- Net margin (net income / revenue). XBRL Net income: us-gaap:NetIncomeLoss; Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax; Revenue: us-gaap:Revenues.
- Diluted EPS. XBRL not reported.
- Free cash flow (operating cash flow − capital expenditure). XBRL Operating cash flow: us-gaap:NetCashProvidedByUsedInOperatingActivities; Capital expenditure: us-gaap:PaymentsToAcquirePropertyPlantAndEquipment.

Each value links to the filing it came from. d marks a derived value. A ratio is not reported when any input is missing.

## Insider purchases and sales

The last 20 open-market transactions on Form 4 (codes P and S). Reported price is as stated on the form, not a market price. [All insider transactions](/companies/lfst/insiders.md)

None in coverage.

## Funds that report holding it

From each manager’s latest Form 13F, largest reported value first. Reported value is as filed: filing data, not a price. [All funds](/funds.md)

| Fund | Quarter ended | Reported value | Shares | Put or call | Change on the quarter before |
| --- | --- | ---: | ---: | --- | --- |
| [TPG GP A, LLC](/funds/1903793.md) | 2026-06-30 | $1.20bn | 111,744,614 |  | Reduced −28,281,943 |
| [FMR LLC](/funds/315066.md) | 2026-06-30 | $623.9m | 58,252,466 |  | Reduced −433,014 |
| [BlackRock, Inc.](/funds/2012383.md) | 2026-06-30 | $389.3m | 36,348,507 |  | Added +18,213,556 |
| [SUMMIT PARTNERS L P](/funds/830588.md) | 2026-06-30 | $249.7m | 23,310,115 |  | Reduced −5,899,661 |
| [VANGUARD PORTFOLIO MANAGEMENT LLC](/funds/2100121.md) | 2026-06-30 | $149.5m | 13,960,892 |  | Added +4,278,587 |
| [JENNISON ASSOCIATES LLC](/funds/53417.md) | 2026-06-30 | $129.4m | 12,077,557 |  | Added +1,848,756 |
| [DIMENSIONAL FUND ADVISORS LP](/funds/354204.md) | 2026-06-30 | $122.4m | 11,427,602 |  | Added +1,059,922 |
| [VANGUARD CAPITAL MANAGEMENT LLC](/funds/2100119.md) | 2026-06-30 | $104.3m | 9,735,076 |  | Added +1,826,917 |
| [STATE STREET CORP](/funds/93751.md) | 2026-06-30 | $88.1m | 8,228,351 |  | Added +4,134,857 |
| [UBS AM, a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC](/funds/861177.md) | 2026-06-30 | $63.7m | 5,947,600 |  | Reduced −144,623 |

## Recent filings

[All 498 filings](/companies/lfst/filings.md)

| Filed | Accepted | Form | What it is | Accession |
| --- | --- | --- | --- | --- |
| 2026-10-16 | 21:26 ET | [8-K](/filings/0001193125-26-424294.md) | 5.02 Departure or appointment of officers or directors | 0001193125-26-424294 |
| 2026-09-11 | 20:24 ET | [8-K](/filings/0001193125-26-389315.md) | 8.01 Other events; 9.01 Financial statements and exhibits | 0001193125-26-389315 |
| 2026-08-06 | 20:21 ET | [10-Q](/filings/0001193125-26-338107.md) | Quarterly report, period 2026-06-30 | 0001193125-26-338107 |
| 2026-08-06 | 00:21 ET | [8-K](/filings/0001193125-26-336057.md) | 2.02 Results of operations; 7.01 Regulation FD disclosure; 8.01 Other events; 9.01 Financial statements and exhibits | 0001193125-26-336057 |
| 2026-07-07 | 20:27 ET | [8-K](/filings/0001193125-26-297525.md) | 5.02 Departure or appointment of officers or directors | 0001193125-26-297525 |
| 2026-06-04 | 20:46 ET | [8-K](/filings/0001193125-26-257606.md) | 5.07 Shareholder vote results | 0001193125-26-257606 |
| 2026-05-12 | 20:43 ET | [8-K](/filings/0001193125-26-219669.md) | 8.01 Other events; 9.01 Financial statements and exhibits | 0001193125-26-219669 |
| 2026-05-07 | 20:00 ET | [10-Q](/filings/0001193125-26-211814.md) | Quarterly report, period 2026-03-31 | 0001193125-26-211814 |
| 2026-05-07 | 23:43 ET | [8-K](/filings/0001193125-26-209709.md) | 2.02 Results of operations; 7.01 Regulation FD disclosure; 9.01 Financial statements and exhibits | 0001193125-26-209709 |
| 2026-04-22 | 21:08 ET | [DEF 14A](/filings/0001193125-26-170798.md) | Proxy statement, period 2026-06-02 | 0001193125-26-170798 |

## Latest annual report

[Form 10-K for the fiscal year ended Dec 31, 2025](/filings/0001193125-26-071462.md), filed Feb 25, 2026.

## Forecast league

Q3 FY2026, the quarter ended 2026-09-30, is open for forecasts until the first results filing for it is accepted by EDGAR. Results are due by \[object Promise\]. [Forecast this quarter](/leagues/2026q3/targets/49ae621e-5181-46fc-a52c-9d6e4f5fa15a)

## About the filer

- CIK: 1845257
- Tickers: LFST
- Exchange: Nasdaq
- SIC code: 8000 Services-Health Services
- State of incorporation: DE
- Filer category: Large accelerated filer

Source: SEC EDGAR, XBRL company facts, the filing index and Forms 4. Last ingested by Listed: Oct 24, 2026, 15:49 ET. No prices; not investment advice.